Adverse events following trivalent inactivated influenza vaccination in children: Analysis of the vaccine adverse event reporting system

Pediatric Infectious Disease Journal

Volumn 30, Issue 1, 2011, Pages

  Muhammad, Riyadh D ^a   Haber, Penina ^b   Broder, Karen R ^b   Leroy, Zanie ^b   Ball, Robert ^a   Braun, M Miles ^a   Davis, Robert L ^b   McMahon, Ann W ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

adverse event; influenza vaccine; vaccine safety

Indexed keywords

IMMUNOGLOBULIN; INFLUENZA VACCINE; TRIPLE VACCINE; INACTIVATED VACCINE;

ABNORMAL LABORATORY RESULT; ADOLESCENT; ANAPHYLAXIS; APNEA; ARTICLE; ASTHMA; BAYES THEOREM; BRAIN INFECTION; CHILD; COUGHING; DATA MINING; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EDEMA; ERYTHEMA MULTIFORME; GUILLAIN BARRE SYNDROME; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE REACTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MEDICATION ERROR; MYALGIA; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; URTICARIA; VASODILATATION; VOMITING; ADVERSE EFFECTS; INFANT; INFLUENZA, HUMAN; VACCINATION;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION; VACCINES, INACTIVATED;

EID: 78650799872     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181ff9795     Document Type: Article

References (58)

1. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002;185:147-152.
2. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med. 2002; 156:986-991.
3. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113:585-593.
4. Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190:1369-1373.
5. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. (Pubitemid 36068705)
6. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353:2559-2567.
7. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. Morb Mortal Wkly Rep. 2008;57(RR-07):1-60.
8. Centers for Disease Control and Prevention (CDC). Recommendation of the Immunization Practices Advisory Committee. Influenza vaccines, 1983- 1984. Morb Mortal Wkly Rep. 1983;32:333-337.
9. Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2003;52(RR-08):1-36.
10. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2004;53(RR-06):1-40.
11. Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2006;55(RR-10):1-42.
12. Wise TG, Dolin R, Mazur MH, et al. Serologic responses and systemic reactions in adults after vaccination with bivalent A/Victoria/75-A/New Jersey/76 and monovalent B/Hong Kong/72 influenza vaccines. J Infect Dis. 1977;136:S507-S517.
13. Gwaltney JM, Adams KF, Hendley JO. Acceptability and antigenicity of influenza A/Victoria/75 virus vaccines in adults of different ages. J Infect Dis. 1977;136:S491-S495.
14. Caplan ES, Hughes TP, O'Donnell S, et al. Reactogenicity and immuno-genicity of parenteral monovalent influenza A/Victoria/3/75 (H3N2) virus vaccine in healthy adults. J Infect Dis. 1977;136:S484-S490.
15. Vellozzi C, Burwen DR, Dobardzic A, et al. Safety of trivalent inactivated influenza vaccine in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27:2114-2120.
16. McMahon AW, Iskander J, Haber P, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the Vaccine Adverse Event Reporting System, 1990-2003. Pediatrics. 2005;115:453-460.
17. Hambidge SJ, Glanz JM, France EK, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;96:1990-1997.
18. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004;158:1031-1036.
19. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J. 2004;23:287-294. (Pubitemid 38508877)
20. Niu MT, Erwin DE, Braun MM. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine. 2001;19:4627-4634.
21. Chen RT, Rastogi SC, Mullen JR, et al. The vaccine adverse event reporting system (VAERS). Vaccine. 1994;12:542-550.
22. Ellenberg SS, Braun MM. Monitoring the safety of vaccines: assessing the risks. Drug Saf. 2002;25:145-152.
23. Code of Federal Regulations. 21 CFR 600.80. Revised April 1, 2010.
24. Centers for Disease Control and Prevention (CDC). Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. Morb Mortal Wkly Rep. 1999;48:577-581.
25. Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA. 1997;278:1176-1178.
26. Zhou W, Pool V, DeStefano F, et al. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. Pharmaco-epidemiol Drug Saf. 2004;13:505-510.
27. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-93 and 1993-94 influenza vaccines. N Eng J Med. 1998;339: 1797-1802.
28. Verstraeten T, Baughman AL, Cadwell B, et al. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. Am J Epidemiol. 2001;154:1006-1012.
29. Zanardi LR, Haber P, Mootrey GT, et al. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics. 2001;107:E97.
30. Massey JT, Moore TF, Parsons VL, et al. Design and estimation for the National Health Interview Survey, 1985-1994. National Center for Health Statistics. Vital Health Stat. 1989;2(110).
31. United States Government Census Report (2000). Available at: http:// www.census.gov. Accessed April 8, 2008.
32. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53: 177-190.
33. Woo EJ, Ball R, Burwen DR, et al. Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System. Drug Saf. 2008;31:667-674.
34. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005;294:2720-2725.
35. DuMouchel W, Pregibon D. Empirical bayes screening for multi-item associations. In: Proceeding of the Conference on Knowledge Discovery and Data. San Diego, CA: ACM Press; 2001:67-76.
36. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25:381-392.
37. Blendon RJ, DesRoches CM, Benson JM, et al. Experiences with obtaining influenza vaccination among persons in priority groups during a vaccine shortage-United States, October-November, 2004. Morb Mortal Wkly Rep. 2004;53:1153-1155.
38. Centers for Disease Control and Prevention (CDC). Updated interim influenza vaccination recommendations-2004-2005 influenza season. Morb Mortal Wkly Rep. 2004;53:1183-1184.
39. Centers for Disease Control and Prevention (CDC). Outbreak of Swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009. Morb Mortal Wkly Rep. 2009;58:1-3.
40. World Health Organization. Epidemic and Pandemic Alert and Response (EPR)-Influenza A (H1N1): Update 7. Available at: http://www.who.int/ csr/don/2009-05-01/en/index.html. Accessed May 1, 2009.
41. Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine. Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep. 2009; 58(RR-10):1-8.
42. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009 19;302:750-757.
43. Dobardzic A, Izurieta H, Woo EJ, et al. Safety review of the purified chick embryo cell rabies vaccine: data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine. 2007;25:4244-4251.
44. Silvers LE, Ellenberg SS, Wise RP, et al. The epidemiology of fatalities reported to the Vaccine Adverse Event Reporting System 1990-1997. Drug Saf. 2001;10:279-285.
45. American Academy of Pediatrics. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics. 2008;121:1281-1286.
46. Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol. 2010;171:177-188.
47. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112:815-820.
48. Wood RA, Berger M, Dreskin SC, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008; 122:771-777.
49. Varricchio F. Medication errors reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2002;20:3049-3051.
50. Petridou E, Kouri N, Vadala H, et al. Frequency and nature of recorded childhood immunization-related errors in Greece. J Toxicol Clin Toxicol. 2004;42:273-276.
51. To Err is Human: Building a Safer Health System. Available at: http:// books.nap.edu/openbook.php?isbn= 0309068371. Accessed April 6, 2009.
52. Varricchio F, Reed J; VAERS Working Group. Follow-up study of medication errors reported to the vaccine adverse event reporting system (VAERS). South Med J. 2006;99:486-489.
53. Bundy DG, Shore AD, Morlock LL, et al. Pediatric vaccination errors: application of the 5 rights framework to a national error reporting database. Vaccine. 2009;27:3890-3896.
54. CDC. Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, October 2005-February 2006. Morb Mortal Wkly Rep. 2006;55:364-366.
55. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110: 105-123.
56. Haber P, Sejvar J, Mikael Y, et al. Vaccines and Guillain-Barre syndrome-review. Drug Saf. 2009;32:309-323.
57. DeStefano F. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf. 2001;10:403-406.
58. McGrogan A, Madle GC, de Vries CS. The epidemiology of Guillain-Barre syndrome worldwide: a systematic literature review. Neuroepidemiology. 2009;32:150-163.